The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer
- 14 November 2005
- journal article
- research article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 63 (4), 1016-1023
- https://doi.org/10.1016/j.ijrobp.2005.04.021
Abstract
Purpose: Positron emission tomography (PET) with the glucose analog [18F]fluro-2-deoxy-D-glucose (FDG) has been accepted as a valuable tool for the staging of lung cancer, but the use of PET/CT in radiation treatment planning is still not yet clearly defined. By the use of (PET/computed tomography (CT) images in treatment planning, we were able to define a new gross treatment volume using anatomic biologic contour (ABC), delineated directly on PET/CT images. We prospectively addressed three issues in this study: (1) How to contour treatment volumes on PET/CT images, (2) Assessment of the degree of correlation between CT-based gross tumor volume/planning target volume (GTV/PTV) (GTV-CT and PTV-CT) and the corresponding PET/CT-based ABC treatment volumes (GTV-ABC and PTV-ABC), (3) Magnitude of interobserver (radiation oncologist planner) variability in the delineation of ABC treatment volumes (using our contouring method). Methods and Materials: Nineteen patients with Stages II–IIIB non–small-cell lung cancer were planned for radiation treatments using a fully integrated PET/CT device. Median patient age was 74 years (range: 52–82 years), and median Karnofsky performance status was 70. Thermoplastic or vacuum-molded immobilization devices required for conformal radiation therapy were custom fabricated for the patient before the injection of [18]f-FDG. Integrated, coregistered PET/CT images were obtained and transferred to the radiation planning workstation (Xeleris). While the PET data remained obscured, a CT-based gross tumor volume (GTV-CT) was delineated by two independent observers. The PTV was obtained by adding a 1.5-cm margin around the GTV. The same volumes were recontoured using PET/CT data and termed GTV-ABC and PTV-ABC, correspondingly. Results: We observed a distinct "halo" around areas of maximal standardized uptake value (SUV). The halo was identified by its distinct color at the periphery of all areas of maximal SUV uptake, independent of PET/CT gain ratio; the halo had an SUV of 2 ± 0.4 and thickness of 2 mm ± 0.5 mm. Whereas the center of our contoured treatment volume expressed the maximum SUV level, a steady decline of SUV was noted peripherally until SUV levels of 2 ± 0.4 were reached at the peripheral edge of our contoured volume, coinciding with the observed halo region. This halo was always included in the contoured GTV-ABC. Because of the contribution of PET/CT to treatment planning, a clinically significant (≥25%) treatment volume modification was observed between the GTV-CT and GTV-ABC in 10/19 (52%) cases, 5 of which resulted in an increase in GTV-ABC volume vs. GTV-CT. The modification of GTV between CT-based and PET/CT-based treatment planning resulted in an alteration of PTV exceeding 20% in 8 out of 19 patients (42%). Interobserver GTV variability decreased from a mean volume difference of 28.3 cm3 (in CT-based planning) to 9.12 cm3 (in PET/CT-based planning) with a respective decrease in standard deviation (SD) from 20.99 to 6.47. Interobserver PTV variability also decreased from 69.8 cm3 (SD ± 82.76) in CT-based planning to 23.9 cm3 (SD ± 15.31) with the use of PET/CT in planning. The concordance in treatment planning between observers was increased by the use of PET/CT; 16 (84%) had ≤10% difference from mean of GTVs using PET/CT compared to 7 cases (37%) using CT alone (p = 0.0035). Conclusion: Position emission tomography/CT-based radiation treatment planning is a useful tool resulting in modification of GTV in 52% and improvement of interobserver variability up to 84%. The use of PET/CT-based ABC can potentially replace the use of GTV. The anatomic biologic halo can be used for delineation of volumes.Keywords
This publication has 21 references indexed in Scilit:
- Defining a radiotherapy target with positron emission tomographyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- In regard to Paulino and Johnstone: Use of PET and CT imaging data in radiation therapy planning. Int J Radit Oncol Biol Phys 2004;59:4–5International Journal of Radiation Oncology*Biology*Physics, 2004
- A method of target definition in PET-based radiotherapy planningInternational Journal of Radiation Oncology*Biology*Physics, 2004
- A prospective study to evaluate the impact of coregistered PET/CT images on radiotherapy treatment planning for esophageal cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- FDG-PET in radiotherapy treatment planning: Pandora's box?International Journal of Radiation Oncology*Biology*Physics, 2004
- Impact of FDG-PET on radiation therapy volume delineation in non–small-cell lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- Noninvasive Staging of Non-small Cell Lung Cancer*Chest, 2003
- Biological target volume (BTV) determined with dose response data from the correlation between metabolic rate of glucose (MRG) measured with 18F-FDG PET and pathologic complete response (PCR) in stage III non-small cell lung cancer (NSCLC)International Journal of Radiation Oncology*Biology*Physics, 2000
- Astro plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1991